Joaquín Portilla

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop et al. · Clinical Infectious Diseases · 2020 · 273 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Brief Report

Sharon Walmsley, Axel Baumgarten, Juan Berenguer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 219 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

Federico Pulido, José Ramón Arribas, Rafaël Delgado et al. · AIDS · 2008 · 154 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 145 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

José Ramón Arribas, Pierre‐Marie Girard, Roland Landman et al. · The Lancet Infectious Diseases · 2015 · 143 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17